Related Experiment Video
Updated: Jun 28, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management
Paige Hargis1, Hannah Baker1, Brett Wiesen1
1Division of Urology, University of Colorado, Aurora, CO, USA.
Abstract:
High-risk non-muscle-invasive bladder cancer (HR-NMIBC) represents a biologically aggressive disease state with substantial risk of recurrence, progression, and need for radical cystectomy. While intravesical Bacillus Calmette-Guérin (BCG) remains first-line for HR-NMIBC is standard of care, both recurrence and progression have led to the development of novel intravesical agents therapies. This article summarizes key clinical trials that are reshaping the management of HR-NMIBC, with particular emphasis on BCG-unresponsive disease. Approved intravesical and systemic agents demonstrate meaningful response rates and durable disease control in select patient populations. Emerging therapies and combination intravesical chemotherapies further expand the available therapies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Clinical Trials: Overview
Treatment Resistant Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...